| . | Non-responder . | Responder . | P-value . |
|---|---|---|---|
| . | (n = 29) . | (n = 72) . | . |
| Age, years | 66.6 ± 11.3 | 65.5 ± 11.4 | 0.662 |
| Male (%) | 19 (65.5) | 34 (47.2) | 0.148 |
| Hypertension (%) | 8 (27.6) | 23 (31.9) | 0.848 |
| Diabetes mellitus (%) | 9 (31.0) | 25 (34.7) | 0.903 |
| Chronic kidney disease (%) | 4 (13.8) | 9 (12.5) | 1.000 |
| AF/AFL (%) | 9 (31.0) | 12 (16.7) | 0.181 |
| LBBB (%) | 18 (62.1) | 70 (97.2) | <0.001 |
| QRS duration, ms | 156 ± 17 | 167 ± 17 | 0.006 |
| Pre-NYHA classification | 1.000 | ||
| 2 (%) | 13 (44.8) | 34 (47.2) | |
| 3 (%) | 16 (55.2) | 38 (52.8) | |
| Medications | |||
| ACEI/ARBs (%) | 8 (27.6) | 20 (27.8) | 1.000 |
| Sacubitril/valsartan (%) | 20 (69.0) | 52 (72.2) | 0.933 |
| Beta-blockers (%) | 24 (82.8) | 70 (97.2) | 0.031 |
| MRAs (%) | 23 (79.3) | 63 (87.54) | 0.461 |
| Loop diuretics (%) | 26 (89.7) | 63 (87.5) | 1.000 |
| Ivabradine (%) | 10 (34.5) | 24 (33.3) | 1.000 |
| SGLT2 inhibitor (%) | 2 (6.9) | 7 (9.7) | 0.948 |
| Echocardiographic parameters | |||
| LVESV, mL | 138.1 (114.18–205.2) | 140.8 (111.73–198.1) | 0.770 |
| LVEF, % | 25.0 (20.0–30.0) | 24.0 (20.0–29.0) | 0.833 |
| LAVI, mL/m2 | 60.0 (44.0–70.9) | 40.0 (31.5–51.8) | 0.001 |
| RVSP, mmHg | 40.5 (29.8–54.5) | 25.0 (22.0–36.0) | 0.002 |
| E/e′ | 26.7 (14.8–31.8) | 15.8 (11.6–18.9) | <0.001 |
| Implanted CRT type | 0.640 | ||
| CRT-D (%) | 29 (100) | 69 (95.8) | |
| CRT-P (%) | 0 (0) | 3 (3.9) | |
| Post QRS duration, ms | 150 ± 18 | 147 ± 21 | 0.405 |
| Biventricular pacing (%) | 96 ± 4 | 98 ± 2 | 0.058 |
| . | Non-responder . | Responder . | P-value . |
|---|---|---|---|
| . | (n = 29) . | (n = 72) . | . |
| Age, years | 66.6 ± 11.3 | 65.5 ± 11.4 | 0.662 |
| Male (%) | 19 (65.5) | 34 (47.2) | 0.148 |
| Hypertension (%) | 8 (27.6) | 23 (31.9) | 0.848 |
| Diabetes mellitus (%) | 9 (31.0) | 25 (34.7) | 0.903 |
| Chronic kidney disease (%) | 4 (13.8) | 9 (12.5) | 1.000 |
| AF/AFL (%) | 9 (31.0) | 12 (16.7) | 0.181 |
| LBBB (%) | 18 (62.1) | 70 (97.2) | <0.001 |
| QRS duration, ms | 156 ± 17 | 167 ± 17 | 0.006 |
| Pre-NYHA classification | 1.000 | ||
| 2 (%) | 13 (44.8) | 34 (47.2) | |
| 3 (%) | 16 (55.2) | 38 (52.8) | |
| Medications | |||
| ACEI/ARBs (%) | 8 (27.6) | 20 (27.8) | 1.000 |
| Sacubitril/valsartan (%) | 20 (69.0) | 52 (72.2) | 0.933 |
| Beta-blockers (%) | 24 (82.8) | 70 (97.2) | 0.031 |
| MRAs (%) | 23 (79.3) | 63 (87.54) | 0.461 |
| Loop diuretics (%) | 26 (89.7) | 63 (87.5) | 1.000 |
| Ivabradine (%) | 10 (34.5) | 24 (33.3) | 1.000 |
| SGLT2 inhibitor (%) | 2 (6.9) | 7 (9.7) | 0.948 |
| Echocardiographic parameters | |||
| LVESV, mL | 138.1 (114.18–205.2) | 140.8 (111.73–198.1) | 0.770 |
| LVEF, % | 25.0 (20.0–30.0) | 24.0 (20.0–29.0) | 0.833 |
| LAVI, mL/m2 | 60.0 (44.0–70.9) | 40.0 (31.5–51.8) | 0.001 |
| RVSP, mmHg | 40.5 (29.8–54.5) | 25.0 (22.0–36.0) | 0.002 |
| E/e′ | 26.7 (14.8–31.8) | 15.8 (11.6–18.9) | <0.001 |
| Implanted CRT type | 0.640 | ||
| CRT-D (%) | 29 (100) | 69 (95.8) | |
| CRT-P (%) | 0 (0) | 3 (3.9) | |
| Post QRS duration, ms | 150 ± 18 | 147 ± 21 | 0.405 |
| Biventricular pacing (%) | 96 ± 4 | 98 ± 2 | 0.058 |
Data are expressed as the mean ± standard deviation, median (IQR), and absolute numbers (%).
ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; AFL, atrial flutter; ARB, angiotensin receptor blocker; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; NYHA, New York Heart Association; MRAs, mineralocorticoid receptor antagonists; LAVI, left atrial volume index; LBBB, left bundle branch block; LVEDV, end-diastolic volume of the left ventricle; LVEF, left ventricular ejection fraction; LVESV, end-systolic volume of the left ventricle; RVSP, right ventricular systolic pressure; SGLT2, sodium-glucose cotransporter-2.
| . | Non-responder . | Responder . | P-value . |
|---|---|---|---|
| . | (n = 29) . | (n = 72) . | . |
| Age, years | 66.6 ± 11.3 | 65.5 ± 11.4 | 0.662 |
| Male (%) | 19 (65.5) | 34 (47.2) | 0.148 |
| Hypertension (%) | 8 (27.6) | 23 (31.9) | 0.848 |
| Diabetes mellitus (%) | 9 (31.0) | 25 (34.7) | 0.903 |
| Chronic kidney disease (%) | 4 (13.8) | 9 (12.5) | 1.000 |
| AF/AFL (%) | 9 (31.0) | 12 (16.7) | 0.181 |
| LBBB (%) | 18 (62.1) | 70 (97.2) | <0.001 |
| QRS duration, ms | 156 ± 17 | 167 ± 17 | 0.006 |
| Pre-NYHA classification | 1.000 | ||
| 2 (%) | 13 (44.8) | 34 (47.2) | |
| 3 (%) | 16 (55.2) | 38 (52.8) | |
| Medications | |||
| ACEI/ARBs (%) | 8 (27.6) | 20 (27.8) | 1.000 |
| Sacubitril/valsartan (%) | 20 (69.0) | 52 (72.2) | 0.933 |
| Beta-blockers (%) | 24 (82.8) | 70 (97.2) | 0.031 |
| MRAs (%) | 23 (79.3) | 63 (87.54) | 0.461 |
| Loop diuretics (%) | 26 (89.7) | 63 (87.5) | 1.000 |
| Ivabradine (%) | 10 (34.5) | 24 (33.3) | 1.000 |
| SGLT2 inhibitor (%) | 2 (6.9) | 7 (9.7) | 0.948 |
| Echocardiographic parameters | |||
| LVESV, mL | 138.1 (114.18–205.2) | 140.8 (111.73–198.1) | 0.770 |
| LVEF, % | 25.0 (20.0–30.0) | 24.0 (20.0–29.0) | 0.833 |
| LAVI, mL/m2 | 60.0 (44.0–70.9) | 40.0 (31.5–51.8) | 0.001 |
| RVSP, mmHg | 40.5 (29.8–54.5) | 25.0 (22.0–36.0) | 0.002 |
| E/e′ | 26.7 (14.8–31.8) | 15.8 (11.6–18.9) | <0.001 |
| Implanted CRT type | 0.640 | ||
| CRT-D (%) | 29 (100) | 69 (95.8) | |
| CRT-P (%) | 0 (0) | 3 (3.9) | |
| Post QRS duration, ms | 150 ± 18 | 147 ± 21 | 0.405 |
| Biventricular pacing (%) | 96 ± 4 | 98 ± 2 | 0.058 |
| . | Non-responder . | Responder . | P-value . |
|---|---|---|---|
| . | (n = 29) . | (n = 72) . | . |
| Age, years | 66.6 ± 11.3 | 65.5 ± 11.4 | 0.662 |
| Male (%) | 19 (65.5) | 34 (47.2) | 0.148 |
| Hypertension (%) | 8 (27.6) | 23 (31.9) | 0.848 |
| Diabetes mellitus (%) | 9 (31.0) | 25 (34.7) | 0.903 |
| Chronic kidney disease (%) | 4 (13.8) | 9 (12.5) | 1.000 |
| AF/AFL (%) | 9 (31.0) | 12 (16.7) | 0.181 |
| LBBB (%) | 18 (62.1) | 70 (97.2) | <0.001 |
| QRS duration, ms | 156 ± 17 | 167 ± 17 | 0.006 |
| Pre-NYHA classification | 1.000 | ||
| 2 (%) | 13 (44.8) | 34 (47.2) | |
| 3 (%) | 16 (55.2) | 38 (52.8) | |
| Medications | |||
| ACEI/ARBs (%) | 8 (27.6) | 20 (27.8) | 1.000 |
| Sacubitril/valsartan (%) | 20 (69.0) | 52 (72.2) | 0.933 |
| Beta-blockers (%) | 24 (82.8) | 70 (97.2) | 0.031 |
| MRAs (%) | 23 (79.3) | 63 (87.54) | 0.461 |
| Loop diuretics (%) | 26 (89.7) | 63 (87.5) | 1.000 |
| Ivabradine (%) | 10 (34.5) | 24 (33.3) | 1.000 |
| SGLT2 inhibitor (%) | 2 (6.9) | 7 (9.7) | 0.948 |
| Echocardiographic parameters | |||
| LVESV, mL | 138.1 (114.18–205.2) | 140.8 (111.73–198.1) | 0.770 |
| LVEF, % | 25.0 (20.0–30.0) | 24.0 (20.0–29.0) | 0.833 |
| LAVI, mL/m2 | 60.0 (44.0–70.9) | 40.0 (31.5–51.8) | 0.001 |
| RVSP, mmHg | 40.5 (29.8–54.5) | 25.0 (22.0–36.0) | 0.002 |
| E/e′ | 26.7 (14.8–31.8) | 15.8 (11.6–18.9) | <0.001 |
| Implanted CRT type | 0.640 | ||
| CRT-D (%) | 29 (100) | 69 (95.8) | |
| CRT-P (%) | 0 (0) | 3 (3.9) | |
| Post QRS duration, ms | 150 ± 18 | 147 ± 21 | 0.405 |
| Biventricular pacing (%) | 96 ± 4 | 98 ± 2 | 0.058 |
Data are expressed as the mean ± standard deviation, median (IQR), and absolute numbers (%).
ACEI, angiotensin-converting enzyme inhibitor; AF, atrial fibrillation; AFL, atrial flutter; ARB, angiotensin receptor blocker; CRT, cardiac resynchronization therapy; CRT-D, cardiac resynchronization therapy defibrillator; CRT-P, cardiac resynchronization therapy pacemaker; NYHA, New York Heart Association; MRAs, mineralocorticoid receptor antagonists; LAVI, left atrial volume index; LBBB, left bundle branch block; LVEDV, end-diastolic volume of the left ventricle; LVEF, left ventricular ejection fraction; LVESV, end-systolic volume of the left ventricle; RVSP, right ventricular systolic pressure; SGLT2, sodium-glucose cotransporter-2.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
